Development and Commercialization of New Materials Centered on Composite Nanoparticles
First written in FY2016-Q3. 21 of 32 entries say "Restated". Latest entry: 2026-11-06.
61 other companies' latest entry also says "Advanced".
- 2026-11-06AdvancedResults
「当社独自のナノ粒子複合化技術を応用した育毛剤やオーラルケア商品を含めたマテリアルビジネスの拡大」
複合ナノ粒子技術の展開対象として、育毛剤を含むマテリアルビジネスの拡大を明示した。 - FY2026-H1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2025AdvancedAnnual report
「During the consolidated fiscal year, an increased-volume version was newly launched in response to customer feedback. The medicated toothpaste Nanoral Medicated White & Protect delivers antibacterial ingredients gradually as nanoparticles containing those ingredients penetrate periodontal pockets, producing an excellent effect in improving periodontal disease.」
An increased-volume version of the Nanoral oral care technology completed in the previous fiscal year was newly launched in response to customer feedback. - FY2025-H1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2024AdvancedAnnual report
「During the consolidated fiscal year, we completed the new oral care technology NanoralⓇ based on the results of industry-academia collaborative research, including clinical trials. The first product, the medicated toothpaste Nanoral Medicated White & Protect, delivers antibacterial ingredients gradually as nanoparticles containing those ingredients penetrate periodontal pockets, producing an excellent effect in improving periodontal disease. Sales under a B2C model began in April, and the product has been particularly well received by senior customers.」
Oral care technology using functional nanoparticles was completed, and B2C sales of the medicated toothpaste were launched. - FY2024-Q2RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles continue to be reiterated as an ongoing business area. - FY2024-Q1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2023AdvancedAnnual report
「In fiscal 2023, we achieved the fusion of this nanoparticle technology and regenerative medicine technology, completing nano-bio technology for functional cosmetics and hair-growth products.」
Functional cosmetics and hair-growth technology combining nanoparticle technology and regenerative medicine technology was completed, and its application to in-house and ODM products, including PLGAns and eyelash serum, and sales were advanced. - FY2023-Q3RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2023-Q2RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area. - FY2023-Q1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles continue to be reiterated as an ongoing business area. - FY2022AdvancedAnnual report
「During the consolidated fiscal year, we began collaborating in June with an advanced regenerative medicine institution and invited a technical adviser from the institution to begin new R&D aimed at developing formulations for nano-technology functional cosmetics and hair-growth products applying regenerative medicine technology. As the first product, we jointly developed M-CEL, a human stem cell conditioned medium that may enhance cosmetic and hair-growth effects. By incorporating M-CEL, encapsulated in PLGA nanoparticles, into the latest in-house eyelash serum, relaunched in September, we significantly enhanced its cosmetic functions. We also began providing M-CEL itself for ODM applications. For our flagship hair-growth product Nano Impact, basic research to optimise the types and quantities of active ingredients enabled us to successfully develop our strongest hair-growth formulation compared with our previous technology. The eighth-generation Nano Impact product, NP-8, was launched in September.」
Specific progress in new materials and commercialisation based on PLGA technology was described, including collaboration with an advanced regenerative medicine institution, the joint development and ODM provision of M-CEL, its incorporation into eyelash serum, and the launch of the NP-8 hair-growth product. - FY2022-Q3RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2022-Q2RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2022-Q1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2021AdvancedAnnual report
「Particularly in China, an exclusive distributorship agreement for Nano Crisfair and Nano Impact was signed with a local external partner in February this year, and cross-border e-commerce is expanding. In the B2B business applying PLGA technology, we develop and provide ODM products, including cosmetics and hair-growth products bearing the customer’s trademark, tailored to the specific needs of each partner. In addition, in the contract research business for DDS (drug delivery systems), we have begun collaborating with a major pharmaceutical company to build a GMP-compliant production platform for PLGA nanoparticle formulations.」
For cosmetics and hair-growth products applying PLGA technology, an exclusive distributorship agreement and cross-border e-commerce in China were pursued, while ODM provision and contract research collaboration for DDS with a major pharmaceutical company were launched. - FY2021-Q2RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2021-Q1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2020-Q3RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2020-Q1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area. - FY2019-Q3RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2019-Q2RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2019-Q1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials centered on composite nanoparticles were reiterated as an ongoing business area of the powder-related business. - FY2018AdvancedAnnual report
「New products were developed and sales activities launched, including the ethanol-free, low-irritation quasi-drug hair-growth product Nano Impact Alcohol Free, which applies PLGA technology, and Eye Cream, a functional cosmetic designed to improve wrinkles around the eyes.」
A hair-growth product and functional cosmetics applying PLGA technology were newly developed and sales activities launched. - FY2018-Q3RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials were reiterated as an ongoing business area of the powder-related business. - FY2018-Q2RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials were reiterated as an ongoing business area of the powder-related business. - FY2018-Q1RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials were reiterated as an ongoing business area of the powder-related business. It was stated that there had been no material change in R&D activities. - FY2017AdvancedAnnual report
「During the consolidated fiscal year, we newly developed and began selling the PLGA-based eyelash serum Irish Serum in response to specific customer needs.」
A new product applying PLGA nanoparticle technology was developed and sales activities were launched. Aggressive sales activities are also being conducted for NOB-VC. - FY2017-Q3RestatedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
The development and commercialisation of new materials were reiterated as an ongoing business area in the description of the powder-related business. - FY2017-Q1Termination of the PLGA technology licence agreementAnnual report
「The licence agreement for the PLGA nanoparticle manufacturing technology between the Company and Nomura Office Co., Ltd. was terminated effective 6 December 2016.」
The existing licence agreement for PLGA nanoparticle manufacturing technology was terminated. As this does not state that overall new material development had ended, it is recorded as a change relating to the agreement. - FY2016AdvancedAnnual report
「The NOB-VC dry particle composite processing system was developed and scheduled for commercial launch. Its maximum effective capacity is approximately 5 times that of conventional equipment, and its cost reduction rate, compared with equipment using the same power input, is at least 30%.」
Specific progress in the commercialisation and practical application of technologies related to new materials and nanoparticles was described, including the development and launch of sales of NOB-VC and the grant of a patent for PLGA nanoparticle technology. - FY2016-Q3First statedAnnual report
「Development and commercialisation of new materials centered on composite nanoparticles」
Research and development and commercialisation of new materials are identified as specific initiatives. R&D expenses for the cumulative third-quarter period were ¥554 million.